Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Survivorship Care Plan Use Lagging
By
Rosemary Frei, MSc
Survivorship
,
Survivorship Care
,
Policies & Guidelines
May 2014, Vol 5, No 4
Cancer centers are ramping up their efforts to create survivorship care plans (SCPs) for all of their patients. However, according to a new survey conducted in 2013, they still have far to go before January 1, 2015, when the American College of Surgeons Commission on Cancer (CoC) accreditation requirement of creating SCPs for all patients comes into effect (Birken SA, et al.
J Cancer Educ
. 2014 April 6. Epub ahead of print)
Read More
Emerging Targeted Therapies for Advanced Pancreatic Cancer Show Promise
By
Wayne Kuznar
Pancreatic Cancer
May 2014, Vol 5, No 4
San Francisco, CA—New cytotoxic combinations introduced over the past several years for the treatment of advanced pancreatic adenocarcinoma now constitute the standard of care for the treatment of all stages of the disease. Eileen M. O’Reilly, MD, Gastrointestinal Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York, reviewed emerging treatments at the 2014 Gastrointestinal Cancers Symposium.
Read More
Large Study Supports Regionalization of Gynecologic Cancer Care
By
Charles Bankhead
Society of Gynecologic Oncology
May 2014, Vol 5, No 4
Tampa, FL—Women with gynecologic cancers had significantly better survival when treated at high-volume centers, according to a review of 863,000 cases reported at the 2014 Society of Gynecologic Oncology meeting.
Read More
Preventive Oophorectomy May Not Eliminate Risk for BRCA1-Related Uterine Cancer
By
Charles Bankhead
Society of Gynecologic Oncology
May 2014, Vol 5, No 4
Tampa, FL—Prophylactic salpingo-oophorectomy did not eliminate the risk for a rare but aggressive form of uterine cancer in women with BRCA1 mutations, according to a study reported at the 2014 Society of Gynecologic Oncology meeting.
Read More
Benefits and Risks of Mammography Explored in New Analyses
By
Rosemary Frei, MSc
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
According to a new systematic review of the risks and benefits of breast cancer screening, regular mammography is associated with a 19% reduction in breast cancer mortality, but it is also associated with a 61% cumulative risk of a false-positive result, and approximately 19% of the cases are, in fact, considered overdiagnoses (Pace LE, Keating NL.
JAMA
. 2014;311:1327-1335).
Read More
New Guidelines Expand Pool of Patients Eligible for Sentinel Node Biopsy
By
Alice Goodman
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
The American Society of Clinical Oncology (ASCO) has issued new guidelines for the use of sentinel node biopsy (SNB) in patients with early-stage breast cancer (Lyman GH, et al.
J Clin Oncol
. 2014;32:1365-1383. The newer version expands the use of SNB to a larger group of patients, based on evidence from 9 randomized trials and 13 cohort studies conducted since 2005, when the first SNB guidelines were published.
Read More
Up Next for the Center for Medicare and Medicaid Innovation: Cancer
By
Ross D. Margulies, JD, MPH
;
Jayson Slotnik, JD, MPH
Health Policy
,
Policies & Guidelines
May 2014, Vol 5, No 4
In passing the Affordable Care Act (ACA) in 2010, Congress had as one of its central goals the creation of new, innovative ways of paying for and delivering healthcare services. With this goal in mind, the ACA established the Center for Medicare and Medicaid Innovation (CMMI), which is tasked with developing new payment and service delivery models to “demo” and, if successful, to eventually roll out nationwide.
Read More
Recent HHS Reports Highlight Need to Address Drug Shortages
By
James Cohen, JD
;
Michael Ryan, JD
;
John Warren, JD
Health Policy
,
Policies & Guidelines
May 2014, Vol 5, No 4
In recent years, an increasing number of drug shortages have threatened public health by reducing—if not eliminating—patient access to critical pharmaceuticals.
Read More
Multigene Testing for Breast Cancer May Be Beneficial
By
Rosemary Frei, MSc
Personalized Medicine
May 2014, Vol 5, No 4
Las Vegas, NV—Researchers are making a compelling case for screening women at high risk for breast cancer for more than
BRCA
mutations. In fact, 4 genetic mutations are well recognized in genetic-based breast cancer, including
CDH1
,
PTEN
,
STK11
, and
TP53
.
Read More
Simple Blood Test Predicts Response to Enzalutamide in Patients with Prostate Cancer
By
Phoebe Starr
Personalized Medicine
May 2014, Vol 5, No 4
San Diego, CA—A preliminary study from a highly respected group of researchers suggests that a simple blood test for the androgen receptor splice variant-7 (AR-V7) in the AR gene can identify men with castrate-resistant prostate cancer (CRPC) who will not respond to enzalutamide (Xtandi).
Read More
Page 232 of 329
229
230
231
232
233
234
235
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
Peer Navigation Intervention Aims to Boost Childhood Cancer Clinical Trial Participation
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma